Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
about
Applications of CYP450 testing in the clinical settingSyncopal episodes associated with cisapride and concurrent drugs.Pharmacogenetics of the proton pump inhibitors: a systematic review.Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjectsDifferent inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypesEnantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypesIncreased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.Stereoselectivity in drug metabolism.Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.Clinical pharmacokinetics of fexofenadine enantiomers.Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.Buspirone, fexofenadine, and omeprazole: quantification of probe drugs and their metabolites in human plasma.Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole.The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.Influence of azimilide on CYP2C19-mediated metabolism.Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes.Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.Pharmacokinetic differences between lansoprazole enantiomers in rats.Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.
P2860
Q24621760-69F8666C-5643-4EEA-8BFB-83BCD4D92177Q33175671-A5D72FB1-8A47-4B12-AC10-6CE25934D28AQ34532600-FA6EE641-D47B-442B-88A4-F73FB12142DCQ34706721-61B84088-B0F1-4F5F-B55C-3F31D4FD4F1AQ35803627-82FE5E35-F1C8-4F77-B0DB-FD9F33346A7CQ35825470-4C0B7BF1-F79A-4C71-8E70-3C2FB5549E83Q35826075-FE905F64-4FCA-4D9E-8E13-D214441C290EQ35827117-D9A46A02-A915-45B6-976D-8DD34A0A1304Q35827444-F2735728-1681-43B5-AD0E-41C57B07E1AEQ36729190-6ED5FFC4-6DD9-40C8-9ED7-420BA0570E06Q36788391-ACD52145-5ED4-4514-967B-7D811FFC4598Q36887128-5FA354DC-8ECA-4960-855D-A63FD21E49EDQ37641373-1554FD69-3757-4073-BAB3-06F5E9D6A6B2Q38514724-846528E6-C40B-4F56-B908-334F8A139DDBQ42063808-6420CB9B-231F-4892-90C4-4A0FC8681960Q43742706-9EF0F6BC-DB4C-4F51-BF97-2AB1D981B15FQ44149312-76654A8C-75B4-471F-B997-26480D3B4E53Q44396463-D6A531C3-7C51-47C4-8291-3211612A88E9Q44820362-E4A06637-EFF1-4AB0-B965-E5DC8C905D40Q44990286-85C08BEF-2B93-4399-B574-811D0CCCFF9DQ46596721-DE49965D-6A5C-4E09-A537-FAF97318DD6BQ50449208-3DA00574-F667-4FAF-A9BE-C53D55F827ABQ51482529-A9BA5EC8-3525-4370-B5BC-14A8D11984BBQ55280841-6D216BC8-5349-468D-90D4-3E69979C54CB
P2860
Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Enantioselective hydroxylation ...... C19 in Swedish white subjects.
@en
type
label
Enantioselective hydroxylation ...... C19 in Swedish white subjects.
@en
prefLabel
Enantioselective hydroxylation ...... C19 in Swedish white subjects.
@en
P2093
P2860
P1476
Enantioselective hydroxylation ...... C19 in Swedish white subjects.
@en
P2093
P2860
P304
P356
10.1016/S0009-9236(97)90060-6
P407
P577
1997-08-01T00:00:00Z